Hudkins RL - Search Results

1

Knowledge-Based, Central Nervous System (CNS) Lead Selection and Lead Optimization for CNS Drug Discovery.

Ghose AK, Herbertz T, Hudkins RL, Dorsey BD, Mallamo JP. Ghose AK, et al. Among authors: hudkins rl. ACS Chem Neurosci. 2012 Jan 18;3(1):50-68. doi: 10.1021/cn200100h. Epub 2011 Nov 2. ACS Chem Neurosci. 2012. PMID: 22267984 Free PMC article.

2

Amine-constrained pyridazinone histamine H₃ receptor antagonists.

Sundar BG, Bailey T, Bacon E, Aimone L, Huang Z, Lyons J, Raddatz R, Hudkins R. Sundar BG, et al. Bioorg Med Chem Lett. 2011 Sep 15;21(18):5543-6. doi: 10.1016/j.bmcl.2011.06.094. Epub 2011 Jul 22. Bioorg Med Chem Lett. 2011. PMID: 21824776

3

Optimization of 5-pyridazin-3-one phenoxypropylamines as potent, selective histamine H₃ receptor antagonists with potent cognition enhancing activity.

Tao M, Aimone LD, Huang Z, Mathiasen J, Raddatz R, Lyons J, Hudkins RL. Tao M, et al. Among authors: hudkins rl. J Med Chem. 2012 Jan 12;55(1):414-23. doi: 10.1021/jm201295j. Epub 2011 Dec 21. J Med Chem. 2012. PMID: 22107017

4

Histamine H3 antagonists for treatment of cognitive deficits in CNS diseases.

Raddatz R, Tao M, Hudkins RL. Raddatz R, et al. Among authors: hudkins rl. Curr Top Med Chem. 2010;10(2):153-69. doi: 10.2174/156802610790411027. Curr Top Med Chem. 2010. PMID: 20166960 Review.

5

Targeting the JNK pathway for therapeutic benefit in CNS disease.

Bozyczko-Coyne D, Saporito MS, Hudkins RL. Bozyczko-Coyne D, et al. Among authors: hudkins rl. Curr Drug Targets CNS Neurol Disord. 2002 Feb;1(1):31-49. doi: 10.2174/1568007023339472. Curr Drug Targets CNS Neurol Disord. 2002. PMID: 12769633 Review.

6

Technically Extended MultiParameter Optimization (TEMPO): An Advanced Robust Scoring Scheme To Calculate Central Nervous System Druggability and Monitor Lead Optimization.

Ghose AK, Ott GR, Hudkins RL. Ghose AK, et al. Among authors: hudkins rl. ACS Chem Neurosci. 2017 Jan 18;8(1):147-154. doi: 10.1021/acschemneuro.6b00273. Epub 2016 Oct 26. ACS Chem Neurosci. 2017. PMID: 27741392 Free article.

7

Discovery and characterization of 6-{4-[3-(R)-2-methylpyrrolidin-1-yl)propoxy]phenyl}-2H-pyridazin-3-one (CEP-26401, irdabisant): a potent, selective histamine H3 receptor inverse agonist.

Hudkins RL, Raddatz R, Tao M, Mathiasen JR, Aimone LD, Becknell NC, Prouty CP, Knutsen LJ, Yazdanian M, Moachon G, Ator MA, Mallamo JP, Marino MJ, Bacon ER, Williams M. Hudkins RL, et al. J Med Chem. 2011 Jul 14;54(13):4781-92. doi: 10.1021/jm200401v. Epub 2011 Jun 2. J Med Chem. 2011. PMID: 21634396

8

Discovery of CEP-1347/KT-7515, an inhibitor of the JNK/SAPK pathway for the treatment of neurodegenerative diseases.

Saporito MS, Hudkins RL, Maroney AC. Saporito MS, et al. Among authors: hudkins rl. Prog Med Chem. 2002;40:23-62. doi: 10.1016/s0079-6468(08)70081-x. Prog Med Chem. 2002. PMID: 12516522 Review.

9

Synthesis and structure-activity relationship of 5-pyridazin-3-one phenoxypiperidines as potent, selective histamine H(3) receptor inverse agonists.

Tao M, Aimone LD, Gruner JA, Mathiasen JR, Huang Z, Lyons J, Raddatz R, Hudkins RL. Tao M, et al. Among authors: hudkins rl. Bioorg Med Chem Lett. 2012 Jan 15;22(2):1073-7. doi: 10.1016/j.bmcl.2011.11.118. Epub 2011 Dec 4. Bioorg Med Chem Lett. 2012. PMID: 22197136

10

Synthesis and evaluation of a new series of 1'-cyclobutyl-6-(4-piperidyloxy)spiro[benzopyran-2,4'-piperidine] derivatives as high affinity and selective histamine-3 receptor (H3R) antagonists.

Dandu RR, Lyons JA, Raddatz R, Huang Z, Aimone LD, Hudkins RL. Dandu RR, et al. Among authors: hudkins rl. Bioorg Med Chem Lett. 2012 Mar 15;22(6):2151-3. doi: 10.1016/j.bmcl.2012.01.139. Epub 2012 Feb 8. Bioorg Med Chem Lett. 2012. PMID: 22365751

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results